Regarding BTC, the FDA has recently approved drugs that inhibit IDH1 and FGFR2, genes that are most frequently altered in intrahepatic CCA, but which have also demonstrated efficacy in extrahepatic biliary tract tumours with the same genetic alteration. This evidence concerns the gene FGFR2 and cholangiocarcinoma.